Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CB 103

Next Previous
Drug Profile

CB 103

Alternative Names: CB-103

Latest Information Update: 28 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Swiss Federal Institute of Technology - Lausanne
  • Developer Cellestia Biotech
  • Class Amines; Antineoplastics; Pyrimidines; Small molecules
  • Mechanism of Action Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Breast cancer; Precursor T-cell lymphoblastic leukaemia-lymphoma
  • Phase I/II Adenoid cystic carcinoma; Haematological malignancies; Solid tumours
  • No development reported Graft-versus-host disease

Most Recent Events

  • 28 Sep 2025 No recent reports of development identified for phase-I development in Graft-versus-host-disease in Switzerland (PO)
  • 11 Jan 2024 Cellestia Biotech plans a proof of concept clinical trial for Graft-versus-host disease
  • 19 Dec 2023 Cellestia Biotech and MedSIR terminates the phase II CAILA trial in Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (PO, Capsule), due to sponsor's decision (NCT04714619)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top